1	范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510. 本文引用 [1]

2	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志, 2018, 26(3): 195-203. 本文引用 [1]

3	LOU TW, YANG RX, FAN JG. The global burden of fatty liver disease: the major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13(1): 119-123. 本文引用 [1]

4	DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(6): e168-e185. 本文引用 [1]

5	SUN DQ, TARGHER G, BYRNE CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr, 2023, 12(3): 386-403. 本文引用 [1]

6	CHEN MT, XIE Y, GONG SL, et al. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis[J]. Pharmacol Res, 2021, 172: 105849. 本文引用 [3]

7	TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. 本文引用 [1]

8	TACKE F, HORN P, WONG VWS, et al. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary[J]. Diabetologia, 2024, 67(11): 2375-2392. 本文引用 [1]

9	HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509. 本文引用 [1]

10	GAWRIEH S, NOUREDDIN M, LOO N, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial[J]. Hepatology, 2021, 74(4): 1809-1824. 本文引用 [1]

11	FRANCQUE SM, BEDOSSA P, RATZIU V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med, 2021, 385(17): 1547-1558. 本文引用 [1]

12	NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. 本文引用 [1]

13	LOOMBA R, ABDELMALEK MF, ARMSTRONG MJ, et al. Semaglutide 2·4 Mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(6): 511-522. 本文引用 [1]

14	HARRISON SA, ALKHOURI N, DAVISON BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study[J]. J Hepatol, 2020, 72(4): 613-626. 本文引用 [1]

15	RATZIU V, DE GUEVARA L, SAFADI R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial[J]. Nat Med, 2021, 27(10): 1825-1835. 本文引用 [1]

16

Pharmaceuticals Galmed.Galmed reports results from the Open-Label part of the ARMoR study showing improvements in histology, imaging, and biomarkers with Aramchol[EB/OL].(2024-10-20)[2023-01-04]. imaging,-and-biomarkers-with-Aramchol. https://galmedpharma.investorroom.com/2023-01-04-Galmed-reports-results-from-the-Open-Label-part-of-the-ARMOR-study-showing-improvements-in-histology 本文引用 [1]

17	YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. 本文引用 [1]

18	RINELLA ME, DUFOUR JF, ANSTEE QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study[J]. J Hepatol, 2022, 76(3): 536-548. 本文引用 [1]

19	RATZIU V, SANYAL A, HARRISON SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72(3): 892-905. 本文引用 [1]

20	ANSTEE QM, NEUSCHWANDER-TETRI BA, WAI-SUN WONG V, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: aurora phase Ⅲ randomized study[J]. Clin Gastroenterol Hepatol, 2024, 22(1): 124-134.e1. 本文引用 [1]

21	trials Clinical. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)(RESOLVE-IT)[EB/OL].(2016-03)[2024-10-20]. https://clinicaltrials.gov/study/NCT02704403 本文引用 [1]

22	HARRISON SA, WONG VWS, OKANOUE T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase Ⅲ STELLAR trials[J]. J Hepatol, 2020, 73(1): 26-39. 本文引用 [1]

23	张卓然, 何新, 郭一, 等. 中医药治疗非酒精性脂肪性肝病的临床研究证据图[J]. 中西医结合肝病杂志, 2024, 34(5): 414-420. 本文引用 [1]

24	DAI L, XU JJ, LIU BC, et al. Lingguizhugan decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach[J]. Front Med, 2022, 16(5): 745-759. 本文引用 [1]

25	LIU QH, LI XJ, PAN YQ, et al. Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial[J]. Phytomedicine, 2024, 130: 155398. 本文引用 [2]

26	潘雨晴, 毛傲洁, 于楚楚, 等. 中药有效成分及其复方防治非酒精性脂肪性肝病的现状与展望[J]. 临床肝胆病杂志, 2024, 40(10): 1933-1941. 本文引用 [1]

27	YANG TT, WANG YY, CAO XY, et al. Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation[J]. Phytomedicine, 2023, 113: 154703. 本文引用 [1]

28	YU MY, ALIMUJIANG M, HU LL, et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver[J]. Int J Biol Sci, 2021, 17(7): 1693-1707. 本文引用 [1]

29	匡双玉. 基于治疗NAFLD的三味中药及有效成分的活性研究[D]. 长沙: 湖南中医药大学, 2014. 本文引用 [1]

30	FENG WW, KUANG SY, TU C, et al. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin[J]. Biomed Pharmacother, 2018, 99: 325-333. 本文引用 [1]

31	CHEN C, XIN X, LIU Q, et al. Geniposide and chlorogenic acid combination improves non-alcoholic fatty liver disease involving the potent suppression of elevated hepatic SCD-1[J]. Front Pharmacol, 2021, 12: 653641. 本文引用 [1]

32	PENG JH, LENG J, TIAN HJ, et al. Geniposide and chlorogenic acid combination ameliorates non-alcoholic steatohepatitis involving the protection on the gut barrier function in mouse induced by high-fat diet[J]. Front Pharmacol, 2018, 9: 1399. 本文引用 [1]

33	SHIMANO H, SATO R. SREBP-regulated lipid metabolism: convergent physiology—divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13: 710-730. 本文引用 [1]

34	MOSLEHI A, HAMIDI-ZAD Z. Role of SREBPs in liver diseases: a mini-review[J]. J Clin Transl Hepatol, 2018, 6(3): 332-338. 本文引用 [1]

35	GUAN DY, BAE H, ZHOU DS, et al. Hepatocyte SREBP signaling mediates clock communication within the liver[J]. J Clin Invest, 2023, 133(8): e163018. 本文引用 [1]

36	GAO ST, WANG TZ, HUANG XK, et al. Exploring the protective effect of Modified Xiaochaihu Decoction against hepatic steatosis and inflammation by network pharmacology and validation in ageing rats[J]. Chin Med, 2020, 15(1): 96. 本文引用 [2]

37	刘静, 孙蓉. 小柴胡汤对非酒精性脂肪性肝炎模型小鼠的保护作用研究[J]. 中草药, 2020, 51(14): 3708-3716. 本文引用 [1]

38	杨钦河, 徐拥建, 冯高飞, 等. 疏肝健脾方药对NASH大鼠原代肝细胞NF-κB信号通路相关基因及蛋白表达的影响[J]. 中药材, 2013, 36(9): 1469-1476. 本文引用 [2]

39	韩莉, 杨钦河, 张玉佩, 等. 疏肝健脾方药对非酒精性脂肪性肝病大鼠Kupffer细胞SREBP-1c信号通路相关基因及蛋白表达的影响[J]. 中成药, 2014, 36(5): 885-892.

40	何秀敏, 杨钦河, 黎佩芳, 等. 疏肝健脾方药对非酒精性脂肪性肝病大鼠肝组织SREBP-1c mRNA及蛋白表达的影响[J]. 中药材, 2011, 34(6): 931-937. 本文引用 [1]

41	YANG SY, ZHAO NJ, LI XJ, et al. Ping-Tang Recipe () improves insulin resistance and attenuates hepatic steatosis in high-fat diet-induced obese rats[J]. Chin J Integr Med, 2012, 18(4): 262-268. 本文引用 [3]

42	LIU MT, HUANG YJ, ZHANG TY, et al. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota[J]. World J Gastroenterol, 2019, 25(27): 3590-3606. 本文引用 [2]

43	苏志威,薛娟,孙俊,等.中医药调控TLR4信号通路干预非酒精性脂肪肝的实验研究进展[J/OL].中国实验方剂学杂志,1-13[2024-12-01]. https://doi.org/10.13422/j.cnki.syfjx.20250698 本文引用 [1]

44	AN LX, WIRTH U, KOCH D, et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases[J]. J Gastrointest Surg, 2022, 26(3): 671-683. 本文引用 [1]

45	李媛媛, 杨钦河, 张金文, 等. 疏肝健脾方药对非酒精性脂肪性肝病大鼠肝细胞TLR4/p38MAPK信号通路的影响[J]. 中国老年学杂志, 2015, 35(23): 6649-6653. 本文引用 [1]

46	ZHANG YR, ZHU XN, ZHENG D, et al. Effects of qutan Huoxue formula on the SOCS1/TLR4 signaling pathway in NASH model mice[J]. Evid Based Complement Alternat Med, 2020, 2020: 1570918. 本文引用 [1]

47	SHU XB, WANG M, XU HC, et al. Extracts of Salvia-nelumbinis naturalis ameliorate nonalcoholic steatohepatitis via inhibiting gut-derived endotoxin mediated TLR4/NF- κ B activation[J]. Evid Based Complement Alternat Med, 2017, 2017: 9208314. 本文引用 [2]

48	YANG QH, XU YJ, LIU YZ, et al. Effects of Chaihu-Shugan-San and Shen-Ling-Bai-Zhu-San on p38 MAPK pathway in kupffer cells of nonalcoholic steatohepatitis[J]. Evid Based Complement Alternat Med, 2014, 2014: 671013. 本文引用 [1]

49	YANG Q, XU Y, FENG G, et al. p38 MAPK signal pathway involved in anti-inflammatory effect of Chaihu-Shugan-San and Shen-Ling-Bai-Zhu-San on hepatocyte in non-alcoholic steatohepatitis rats[J]. Afr J Tradit Complement Altern Med, 2014, 11(1): 213-221. 本文引用 [1]

50	刘静, 庄振杰, 田静, 等. 复方楂金颗粒对NASH小鼠肝脏内TLR4信号通路的影响[J]. 中国中西医结合杂志, 2016, 36(4): 460-465. 本文引用 [1]

51	SMITH BK, MARCINKO K, DESJARDINS EM, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK[J]. Am J Physiol Endocrinol Metab, 2016, 311(4): E730-740. 本文引用 [1]

52	ZHAO P, SUN XL, CHAGGAN C, et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis[J]. Science, 2020, 367(6478): 652-660. 本文引用 [1]

53	LU HF, LAI YH, HUANG HC, et al. Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis, and insulin resistance in mice[J]. J Ginseng Res, 2020, 44(2): 238-246. 本文引用 [1]

54	LIU HK, HUNG TM, HUANG HC, et al. Bai-hu-Jia-Ren-Shen-Tang decoction reduces fatty liver by activating AMP-activated protein kinase in vitro and in vivo [J]. Evid Based Complement Alternat Med, 2015, 2015: 651734. 本文引用 [1]

55	WANG Y, ZHAO HL, LI X, et al. Tangshen formula alleviates hepatic steatosis by inducing autophagy through the AMPK/SIRT1 pathway[J]. Front Physiol, 2019, 10: 494. 本文引用 [1]

56	WANG RQ, MI HM, LI H, et al. Modulation of IKKβ/NF-κB and TGF-β1/Smad via Fuzheng Huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice[J]. Iran J Basic Med Sci, 2015, 18(4): 404-411. 本文引用 [1]

57	姜岑, 宋虹霏, 王东, 等. 基于IKKβ/NF-κB通路研究芪甲柔肝方抗肝纤维化作用机制[J]. 中华中医药杂志, 2022, 37(8): 4805-4809. 本文引用 [1]

58	XIAO LY, LIANG S, GE LL, et al. Si-Wei-Qing-Gan-Tang improves non-alcoholic steatohepatitis by modulating the nuclear factor-κB signal pathway and autophagy in methionine and choline deficient diet-fed rats[J]. Front Pharmacol, 2020, 11: 530. 本文引用 [1]

59	朱晓宁, 汪静, 张玉蓉, 等. 祛痰活血方上调SOCS1抑制TLR4/NF-κB信号通路改善非酒精性脂肪性肝炎小鼠肝损伤[J]. 世界科学技术-中医药现代化, 2020, 22(12): 4293-4299. 本文引用 [1]

60	CHEN H, TAN HB, WAN J, et al. PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets[J]. Pharmacol Ther, 2023, 245: 108391. 本文引用 [1]

61	GROSS B, PAWLAK M, LEFEBVRE P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD[J]. Nat Rev Endocrinol, 2017, 13(1): 36-49. 本文引用 [1]

62	GUO Y, DING PH, LIU LJ, et al. Gegen Qinlian Decoction attenuates high-fat diet-induced steatohepatitis in rats via gut microbiota[J]. Evid Based Complement Alternat Med, 2018, 2018: 7370891. 本文引用 [1]

63	ZHANG CH, XIAO Q, SHENG JQ, et al. Gegen Qinlian Decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways[J]. Biomed Pharmacother, 2020, 126: 110076. 本文引用 [1]

64	XING YF, ZHANG Z, FU WJ, et al. Shugan Xiaozhi Decoction attenuates nonalcoholic steatohepatitis by enhancing PPAR α and L-FABP expressions in high-fat-fed rats[J]. Evid Based Complement Alternat Med, 2016, 2016: 7870189. 本文引用 [1]

65	LAN QP, REN ZT, CHEN Y, et al. Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat[J]. Chin Med, 2021, 16(1): 27. 本文引用 [1]

66	HONG M, JUNG J, PARK HS, et al. Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways[J]. PLoS One, 2017, 12(6): e0178514.a 本文引用 [1]